FW1256 is a phenyl analog. It also a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and causes cell apoptosis. FW1256 shows potent anti-inflammatory effects. It also has the potential for cancer and cardiovascular disease treatment.

FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment obviously decreases IL-1β, COX-2, iNOS PROTE, and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages. FW1256 reduces NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256. FW1256 concentration-dependently reduces TNF-α (IC50: 61.2 μM), IL-6 (IC50: 11.7 μM), PGE2 (IC50: 25.5 μM) and NO (IC50: 34.6 μM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC50s: 414.9 μM, 300.2 μM, 4 μM and 9.5 μM for TNF-α, IL-6, PGE2 and NO, respectively) [1].

Treatment with FW1256 (100 mg/kg; i.p.; male C57BL/6 mice), decreases IL-1β, TNFα, nitrate/nitrite, and PGE2 levels in LPS-treated mice [1].